NasdaqGS - Nasdaq Real Time Price USD

Karyopharm Therapeutics Inc. (KPTI)

4.5000

+0.0100

+(0.22%)

As of 10:10:51 AM EDT. Market Open.

Karyopharm to Present at the Jefferies Global Healthcare Conference

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team is scheduled to present at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025 at 3:10 p.m. ET in New York, NY.

PR Newswire 6 days ago

KPTI
+0.22%
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 566 restricted stock units (RSUs) to two newly-hired employees. These RSU awards were granted as of May 31, 2025 (the "Grant Date") pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended, as inducements material to the new employees entering into employment with Karyopharm in accordance with Nasdaq L

PR Newswire 6 days ago

KPTI
+0.22%
Here's Why Karyopharm Therapeutics (KPTI) Is a Great 'Buy the Bottom' Stock Now

Karyopharm Therapeutics (KPTI) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Zacks 14 days ago

KPTI
+0.22%
Does Karyopharm Therapeutics (KPTI) Have the Potential to Rally 521.62% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 521.6% in Karyopharm Therapeutics (KPTI). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks 21 days ago

KPTI
+0.22%
Karyopharm to Participate at the 2025 RBC Capital Markets Global Healthcare Conference

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate at the 2025 RBC Capital Markets Global Healthcare Conference in a fireside chat on Wednesday, May 21 at 10:00 a.m. ET in New York, NY.

PR Newswire 21 days ago

KPTI
+0.22%
Karyopharm Announces Poster Presentation on Selinexor in Myelofibrosis at the 2025 European Hematology Association Annual Meeting

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced its abstract has been selected for a poster presentation at the 2025 European Hematology Association Annual Meeting (EHA) being held June 12-15 in Milan, Italy. The abstract contains data on selinexor monotherapy in a hard-to-treat, heavily pretreated myelofibrosis patient population from the Phase 2 XPORT-MF-035 trial.

PR Newswire 26 days ago

KPTI
+0.22%
Karyopharm Therapeutics Inc (KPTI) Q1 2025 Earnings Call Highlights: Promising Clinical ...

Karyopharm Therapeutics Inc (KPTI) reports significant progress in myelofibrosis trials and demand growth, despite facing revenue and enrollment hurdles.

GuruFocus.com 27 days ago

KPTI
+0.22%
Karyopharm Therapeutics (KPTI) Reports Q1 Loss, Lags Revenue Estimates

Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of 34.20% and 16.18%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks 27 days ago

KPTI
+0.22%
Karyopharm Therapeutics: Q1 Earnings Snapshot

NEWTON, Mass. AP) — Karyopharm Therapeutics Inc. KPTI) on Monday reported a loss of $23.5 million in its first quarter.

Associated Press Finance 27 days ago

KPTI
+0.22%
Karyopharm Reports First Quarter 2025 Financial Results and Announces New Data in Myelofibrosis that Further Suggests Selinexor May Lead to Meaningful Spleen Volume Reduction, Symptom Improvement, Hemoglobin Stabilization and Disease Modification

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported financial results for the first quarter ended March 31, 2025 and highlighted progress on key clinical development programs.

PR Newswire 27 days ago

KPTI
+0.22%
Karyopharm to Report First Quarter 2025 Financial Results on May 12, 2025

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report first quarter 2025 financial results on Monday, May 12, 2025. Karyopharm's management team will host a conference call and audio webcast at 4:30 p.m. ET on Monday, May 12, 2025, to discuss the financial results and other company updates.

PR Newswire last month

KPTI
+0.22%
Biotech stocks slide as Marks resignation seen being negative for sector

Shares of several biotech and biopharma names are under pressure on Monday following the resignation of the head of the Food and Drug Administration’s Center for Biologics Evaluation and Research, Peter Marks. RBC Capital says the development is “not good for the biotech industry even beyond vaccines.” Voicing a similar opinion, BMO Capital told investors this morning that it sees the news as a “significant negative” for the biopharma and biotech sectors. “NOT GOOD” FOR BIOTECH SECTOR: RBC Capit

TipRanks 2 months ago

GLPG

GLPGF

PTCT
Karyopharm Announces 1-for-15 Reverse Stock Split

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it will implement a 1-for-15 reverse stock split of the issued shares of the Company's common stock ("Reverse Stock Split"), effective at 5:00 p.m. Eastern Time on February 25, 2025. The Reverse Stock Split was approved by the Company's stockholders at the Company's Special Meeting of Stockholders held on January 30, 2025, with the final ratio subsequentl

PR Newswire 3 months ago

KPTI
+0.22%
Karyopharm Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

Karyopharm Therapeutics ( NASDAQ:KPTI ) Full Year 2024 Results Key Financial Results Revenue: US$145.2m (flat on FY...

Simply Wall St. 3 months ago

KPTI
+0.22%
Karyopharm Therapeutics Inc (KPTI) Q4 2024 Earnings Call Highlights: Navigating Revenue ...

Karyopharm Therapeutics Inc (KPTI) reports a mixed financial performance with increased XPOVIO revenue and strategic progress in clinical trials amid revenue and cash flow challenges.

GuruFocus.com 3 months ago

KPTI
+0.22%
Karyopharm Therapeutics (KPTI) Q4 2024 Earnings Call Transcript

KPTI earnings call for the period ending December 31, 2024.

Motley Fool 3 months ago

KPTI
+0.22%
Karyopharm Therapeutics (KPTI) Reports Q4 Loss, Tops Revenue Estimates

Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of 7.69% and 0.83%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 3 months ago

KPTI
+0.22%
Karyopharm Therapeutics: Q4 Earnings Snapshot

The results surpassed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 26 cents per share. The pharmaceutical company posted revenue of $30.5 million in the period.

Associated Press Finance 3 months ago

KPTI
+0.22%
Karyopharm Reports Fourth Quarter and Full Year 2024 Financial Results, Announces Update to Phase 3 XPORT-EC-042 Trial and Highlights Recent Company Progress

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported financial results for the fourth quarter and full year ended December 31, 2024. In addition, Karyopharm highlighted select corporate milestones and provided an overview of its key clinical development programs.

PR Newswire 3 months ago

KPTI
+0.22%
Analysts Estimate Indivior PLC (INDV) to Report a Decline in Earnings: What to Look Out for

Indivior (INDV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks 3 months ago

INDV

KPTI
+0.22%

Performance Overview

Return	KPTI	S&P 500 (^GSPC)
YTD	-55.62%	+2.11%
1-Year	-68.75%	+12.32%
3-Year	-94.96%	+49.47%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Karyopharm Therapeutics Inc. (KPTI)

Karyopharm to Present at the Jefferies Global Healthcare Conference

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Here's Why Karyopharm Therapeutics (KPTI) Is a Great 'Buy the Bottom' Stock Now

Does Karyopharm Therapeutics (KPTI) Have the Potential to Rally 521.62% as Wall Street Analysts Expect?

Karyopharm to Participate at the 2025 RBC Capital Markets Global Healthcare Conference

Karyopharm Announces Poster Presentation on Selinexor in Myelofibrosis at the 2025 European Hematology Association Annual Meeting

Karyopharm Therapeutics Inc (KPTI) Q1 2025 Earnings Call Highlights: Promising Clinical ...

Karyopharm Therapeutics (KPTI) Reports Q1 Loss, Lags Revenue Estimates

Karyopharm Therapeutics: Q1 Earnings Snapshot

Karyopharm Reports First Quarter 2025 Financial Results and Announces New Data in Myelofibrosis that Further Suggests Selinexor May Lead to Meaningful Spleen Volume Reduction, Symptom Improvement, Hemoglobin Stabilization and Disease Modification

Karyopharm to Report First Quarter 2025 Financial Results on May 12, 2025

Biotech stocks slide as Marks resignation seen being negative for sector

Karyopharm Announces 1-for-15 Reverse Stock Split

Karyopharm Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

Karyopharm Therapeutics Inc (KPTI) Q4 2024 Earnings Call Highlights: Navigating Revenue ...

Karyopharm Therapeutics (KPTI) Q4 2024 Earnings Call Transcript

Karyopharm Therapeutics (KPTI) Reports Q4 Loss, Tops Revenue Estimates

Karyopharm Therapeutics: Q4 Earnings Snapshot

Karyopharm Reports Fourth Quarter and Full Year 2024 Financial Results, Announces Update to Phase 3 XPORT-EC-042 Trial and Highlights Recent Company Progress

Analysts Estimate Indivior PLC (INDV) to Report a Decline in Earnings: What to Look Out for

Performance Overview